William J. Jeffcoate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William J. Jeffcoate has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
F. L. Game
Nottingham University Hospitals Trust
6 shared publicationsFran Game
Foot Ulcer Trials Unit, Nottingham University Hospitals Trust, City Hospital Campus, Nottingham, U.K.
3 shared publications- Frances L. Game
Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
3 shared publications G. D. Valk
Department of Internal Medicine, University Medical Center Utrecht, Utrecht
3 shared publicationsK. Bakker
IWGDF, Heemstede, the Netherlands
3 shared publicationsW. H. van Houtum
Department of Internal Medicine, Spaarne Hospital, Hoofddorp, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 22 November 2017
- Published by Wiley in Diabetic Medicine
- Vol. 35 (1) , 8-9
Reducing amputation in diabetes: work from the West Country provides both evidence and a tool‐kit
- 22 November 2017
- Published by Wiley in Diabetic Medicine
- Vol. 35 (1) , 8-9
Open AccessReducing amputation in diabetes: work from the West Country provides both evidence and a tool‐kit
- Open Access
- 10 October 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-8
The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial
Diabetic foot ulcers are a common and severe complication of diabetes mellitus. Standard treatment includes debridement, offloading, management of infection and revascularisation where appropriate, although healing times may be long. The LeucoPatch® device is used to generate an autologous platelet-rich fibrin and leucocyte wound dressing produced from the patient’s own venous blood by centrifugation, but without the addition of any reagents. The final product comprises a thin, circular patch composed predominantly of fibrin together with living platelets and leucocytes. Promising results have been obtained in non-controlled studies this system, but this now needs to be tested in a randomised controlled trial (RCT). If confirmed, the LeucoPatch® may become an important new tool in the armamentarium in the management of diabetic foot ulcers which are hard-to-heal. People with diabetes and hard-to-heal ulcers of the foot will receive either pre-specified good standard care or good standard care supplemented by the application of the LeucoPatch® device. The primary outcome will be the percentage of ulcers healed within 20 weeks. Healing will be defined as complete epithelialisation without discharge that is maintained for 4 weeks and is confirmed by an observer blind to randomisation group. Ulcers of the foot are a major source of morbidity to patients with diabetes and costs to health care economies. The study population is designed to be as inclusive as possible with the aim of maximising the external validity of any findings. The primary outcome measure is healing within 20 weeks of randomisation and the trial also includes a number of secondary outcome measures. Among these are rate of change in ulcer area as a predictor of the likelihood of eventual healing, minor and major amputation of the target limb, the incidence of infection and quality of life. International Standard Randomised Controlled Trial, ISRCTN27665670 . Registered on 5 July 2013.
- 10 October 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-8
Open AccessThe LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial
Diabetic foot ulcers are a common and severe complication of diabetes mellitus. Standard treatment includes debridement, offloading, management of infection and revascularisation where appropriate, although healing times may be long. The LeucoPatch® device is used to generate an autologous platelet-rich fibrin and leucocyte wound dressing produced from the patient’s own venous blood by centrifugation, but without the addition of any reagents. The final product comprises a thin, circular patch composed predominantly of fibrin together with living platelets and leucocytes. Promising results have been obtained in non-controlled studies this system, but this now needs to be tested in a randomised controlled trial (RCT). If confirmed, the LeucoPatch® may become an important new tool in the armamentarium in the management of diabetic foot ulcers which are hard-to-heal. People with diabetes and hard-to-heal ulcers of the foot will receive either pre-specified good standard care or good standard care supplemented by the application of the LeucoPatch® device. The primary outcome will be the percentage of ulcers healed within 20 weeks. Healing will be defined as complete epithelialisation without discharge that is maintained for 4 weeks and is confirmed by an observer blind to randomisation group. Ulcers of the foot are a major source of morbidity to patients with diabetes and costs to health care economies. The study population is designed to be as inclusive as possible with the aim of maximising the external validity of any findings. The primary outcome measure is healing within 20 weeks of randomisation and the trial also includes a number of secondary outcome measures. Among these are rate of change in ulcer area as a predictor of the likelihood of eventual healing, minor and major amputation of the target limb, the incidence of infection and quality of life. International Standard Randomised Controlled Trial, ISRCTN27665670 . Registered on 5 July 2013.
- Open Access
- 1 September 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 4 (9) , 781-788
Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality
- 1 September 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 4 (9) , 781-788
Open AccessReporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality
- 15 April 2015
- Published by Wiley in Diabetic Medicine
- Vol. 32 (6) , 760-770
Charcot foot syndrome
Charcot foot syndrome is an uncommon complication of diabetes but is potentially devastating in its consequences. Outcome is made worse by widespread professional ignorance leading to delayed diagnosis, but it is also hampered by lack of understanding of its causes and lack of treatments with proven effectiveness, other than offloading. There remains a desperate need for studies into its causes as well as comparative audit and trials designed to determine the best treatment for this difficult condition. Such work can probably only be effectively carried out through the establishment of multicentre networks. Nevertheless, improved understanding in recent years of the likely role of inflammatory pathways has raised awareness of the multiple ways in which the effects of neuropathy may be manifest in the development of the Charcot foot. This awareness is also leading to the realization that similar processes may conceivably contribute to the refractoriness of other foot diseases in diabetes, including both chronic unhealing ulcers and osteomyelitis.
- 15 April 2015
- Published by Wiley in Diabetic Medicine
- Vol. 32 (6) , 760-770
Charcot foot syndrome
Charcot foot syndrome is an uncommon complication of diabetes but is potentially devastating in its consequences. Outcome is made worse by widespread professional ignorance leading to delayed diagnosis, but it is also hampered by lack of understanding of its causes and lack of treatments with proven effectiveness, other than offloading. There remains a desperate need for studies into its causes as well as comparative audit and trials designed to determine the best treatment for this difficult condition. Such work can probably only be effectively carried out through the establishment of multicentre networks. Nevertheless, improved understanding in recent years of the likely role of inflammatory pathways has raised awareness of the multiple ways in which the effects of neuropathy may be manifest in the development of the Charcot foot. This awareness is also leading to the realization that similar processes may conceivably contribute to the refractoriness of other foot diseases in diabetes, including both chronic unhealing ulcers and osteomyelitis.
- Open Access
- 26 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 462
Evaluation of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: study protocol for a randomised controlled trial
Ulcers of the heel in diabetes are the source of considerable suffering and cost. In the absence of specific treatments, it has been suggested that removable, lightweight fibreglass heel casts may both promote healing and reduce discomfort and pain. The aim of the study is to assess the effectiveness and cost-effectiveness of fibreglass heel casts in the management of heel ulcers. This is an observer-blind, randomised controlled trial in which participants with diabetes and heel ulcers (NPUAP/EPUAP grades 2, 3 or 4 and present for 2 or more weeks) are randomised to receive either usual care plus lightweight fibreglass heel casts or usual care alone. Randomisation is undertaken by random number sequence generation incorporated as part of the electronic case record form, and is stratified by both ulcer area (less than versus equal to or greater than 1 cm2) and NPUAP/EPUAP grade. Participants are followed every two weeks until healing or for 24 weeks. The primary outcome measure is healing at or before 24 weeks and maintained for 4 weeks. Secondary outcomes include (i) ulcer-related outcomes: time to healing, change in ulcer area, minor and major amputation, secondary infection and (ii) patient-related outcomes: local pain, mood and function (EQ-5D), impact of the ulcer (Cardiff Wound Impact Schedule) and survival. Cost-effectiveness will be assessed using a decision analytic model to estimate costs from the perspective of the UK NHS and personal social services and health outcomes, including percent healing and Quality Adjusted Life Years gained. Safety will be documented as adverse and serious adverse device effects. If it is possible to confirm significant clinical benefit and/or cost-effectiveness, this would have direct implications for the management of this distressing and costly complication of diabetes ISRCTN62524796 Registered 29 March 2011
- 26 November 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 462
Open AccessEvaluation of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: study protocol for a randomised controlled trial
Ulcers of the heel in diabetes are the source of considerable suffering and cost. In the absence of specific treatments, it has been suggested that removable, lightweight fibreglass heel casts may both promote healing and reduce discomfort and pain. The aim of the study is to assess the effectiveness and cost-effectiveness of fibreglass heel casts in the management of heel ulcers. This is an observer-blind, randomised controlled trial in which participants with diabetes and heel ulcers (NPUAP/EPUAP grades 2, 3 or 4 and present for 2 or more weeks) are randomised to receive either usual care plus lightweight fibreglass heel casts or usual care alone. Randomisation is undertaken by random number sequence generation incorporated as part of the electronic case record form, and is stratified by both ulcer area (less than versus equal to or greater than 1 cm2) and NPUAP/EPUAP grade. Participants are followed every two weeks until healing or for 24 weeks. The primary outcome measure is healing at or before 24 weeks and maintained for 4 weeks. Secondary outcomes include (i) ulcer-related outcomes: time to healing, change in ulcer area, minor and major amputation, secondary infection and (ii) patient-related outcomes: local pain, mood and function (EQ-5D), impact of the ulcer (Cardiff Wound Impact Schedule) and survival. Cost-effectiveness will be assessed using a decision analytic model to estimate costs from the perspective of the UK NHS and personal social services and health outcomes, including percent healing and Quality Adjusted Life Years gained. Safety will be documented as adverse and serious adverse device effects. If it is possible to confirm significant clinical benefit and/or cost-effectiveness, this would have direct implications for the management of this distressing and costly complication of diabetes ISRCTN62524796 Registered 29 March 2011
- 1 September 2013
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 26 (9) , 421-428
The Charcot Foot
Charcot joint is an uncommon but often missed complication of the neuropathic diabetic foot. Prompt recognition and treatment with plantar pressure redistribution can prevent unnecessary amputation.
- 1 September 2013
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 26 (9) , 421-428
The Charcot Foot
Charcot joint is an uncommon but often missed complication of the neuropathic diabetic foot. Prompt recognition and treatment with plantar pressure redistribution can prevent unnecessary amputation.
- 6 July 2013
- Published by Springer Nature in BioDrugs
- Vol. 28 (1) , 1-6
Evidence for the Use of Biological Therapies in Ulcers of the Foot in Diabetes
Because the chronic ulcer of the foot in diabetes is often unresponsive to standard care, there has been considerable interest in the potential benefit of so-called “advanced wound therapies”—many of which have a biological basis. This article summarizes the findings of earlier systematic reviews, together with the findings of more recent publications. The available evidence suggests that while some biological therapies offer promise, more work is needed to substantiate their role in clinical practice. This conclusion needs to be placed in the context of very strong observational data demonstrating the major improvements that can accompany changes to the way in which wound care is delivered with, in particular, the introduction of multidisciplinary team work and more rapid referral for expert assessment.
- 6 July 2013
- Published by Springer Nature in BioDrugs
- Vol. 28 (1) , 1-6
Evidence for the Use of Biological Therapies in Ulcers of the Foot in Diabetes
Because the chronic ulcer of the foot in diabetes is often unresponsive to standard care, there has been considerable interest in the potential benefit of so-called “advanced wound therapies”—many of which have a biological basis. This article summarizes the findings of earlier systematic reviews, together with the findings of more recent publications. The available evidence suggests that while some biological therapies offer promise, more work is needed to substantiate their role in clinical practice. This conclusion needs to be placed in the context of very strong observational data demonstrating the major improvements that can accompany changes to the way in which wound care is delivered with, in particular, the introduction of multidisciplinary team work and more rapid referral for expert assessment.
- Open Access
- 18 January 2013
- Published by Springer Nature
Randomised controlled trial of the use of three dressing regimens in the management of chronic ulcers of the foot in diabetes
- 18 January 2013
- Published by Springer Nature
Open AccessRandomised controlled trial of the use of three dressing regimens in the management of chronic ulcers of the foot in diabetes
- 23 January 2012
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 28 (S1) , 85-88
Wound healing – a practical algorithm
Summary: The decision‐making process involved in the management of diabetic foot wounds is complex but hinges on certain simple principles. The first is to agree the actual aim of management with the patient or their representative – and healing of an open wound may be only a part of this. The agreed plan should be discussed and reviewed if the wound is unresponsive to intervention. Management depends otherwise on regular debridement and cleansing, treatment of any infection, consideration of revascularisation and protection of the wound by dressings and off‐loading. The evidence to justify the use of advanced wound care therapies is not strong, and outcome depends more on the organisation of the wound care process than on the choice of a particular wound care product. The introduction of an expert multidisciplinary team has been shown to lead to a very significant reduction in the incidence of major amputation and it is likely that it is the availability or otherwise of prompt expert advice which is the principal explanation of the major variations that are known to exist in the incidence of amputation even within single countries. Copyright © 2012 John Wiley & Sons, Ltd.
- 23 January 2012
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 28 (S1) , 85-88
Wound healing – a practical algorithm
Summary: The decision‐making process involved in the management of diabetic foot wounds is complex but hinges on certain simple principles. The first is to agree the actual aim of management with the patient or their representative – and healing of an open wound may be only a part of this. The agreed plan should be discussed and reviewed if the wound is unresponsive to intervention. Management depends otherwise on regular debridement and cleansing, treatment of any infection, consideration of revascularisation and protection of the wound by dressings and off‐loading. The evidence to justify the use of advanced wound care therapies is not strong, and outcome depends more on the organisation of the wound care process than on the choice of a particular wound care product. The introduction of an expert multidisciplinary team has been shown to lead to a very significant reduction in the incidence of major amputation and it is likely that it is the availability or otherwise of prompt expert advice which is the principal explanation of the major variations that are known to exist in the incidence of amputation even within single countries. Copyright © 2012 John Wiley & Sons, Ltd.
- Open Access
- 31 May 2011
- Published by Wiley in Practical Diabetes International
- Vol. 28 (5) , 238
Amputations and diabetes care: variation in practice
- 31 May 2011
- Published by Wiley in Practical Diabetes International
- Vol. 28 (5) , 238
Open AccessAmputations and diabetes care: variation in practice